BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 21, 2019
View Archived Issues
Broken BBB exposes targeting mechanism
Read More
Early in ALS/FTD, there's targetable toxicity
Read More
FLX Bio presents a novel CCR4 antagonist for the treatment of allergic disorders
Read More
APD-588 inhibits inflammation and airway hyperresponsiveness in model of allergic asthma
Read More
Urine circulating cell-free DNA as biomarker in renal cell carcinoma
Read More
Model suggests gut bacteria cause absorptive hypercalciuria
Read More
Polymorphisms in RAGE gene as biomarkers of survival in urothelial cell carcinoma
Read More
Combination vaccination enhances influenza-specific immunity
Read More
Sustained efficacy seen with zilucoplan in phase II study in patients with myasthenia gravis
Read More
Allergan presents phase III results from ACHIEVE II study of ubrogepant for treating migraine
Read More
CureVac announces sponsored research agreement for mRNA-based eye therapy candidates
Read More
FXR agonists with sustained activity exhibit efficacy in mouse models of colitis
Read More
FDA approves Nayzilam to treat intermittent, stereotypic episodes of frequent seizure activity
Read More
Bristol-Myers Squibb presents new NR1H4 agonists
Read More
Samumed patents DYRK1A and/or GSK-3beta inhibitors
Read More
Phase III fliGHt trial provides new safety data on TransCon Growth Hormone in pediatric patients
Read More
French researchers disclose BRD4 and MYC inhibitors
Read More
Ocular Therapeutics reports topline results from phase III trial of OTX-TP for glaucoma
Read More
Kazia collaborates with Alliance to study GDC-0084 in brain metastases
Read More
AiCuris synthesizes new HBV inhibitors
Read More
Viva Vision Shanghai discloses cell adhesion inhibitory compounds
Read More
Phase III KEYNOTE-119 trial of Keyruda in metastatic TNBC fails to meet primary endpoint
Read More
New German study investigates adrecizumab for cardiogenic shock
Read More
Enrollment opens in new phase IIa study of CC-31244 for ultra-short treatment of hepatitis C
Read More
Oncopeptides begins NDA preparations for melflufen in triple-class refractory multiple myeloma
Read More
Phase III APeX-2 trial of BCX-7353 to prevent HAE attacks meets primary endpoint
Read More